share_log

Alliance Global Partners Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $4

Benzinga Real-time News ·  Jul 20, 2022 09:24

Alliance Global Partners analyst James Molloy maintains Pluristem Therapeutics (NASDAQ:PSTI) with a Buy and lowers the price target from $9.5 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment